Overview

Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerance of changing patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
Phase:
Phase 4
Details
Lead Sponsor:
University of Alabama at Birmingham
Treatments:
Ambrisentan
Bosentan